Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Xian-Yang Li(QIMR Berghofer Medical Research Institute), Mark J. Smyth(Peter MacCallum Cancer Centre), Michael Hölzel(University of Bonn), Corey Smith(QIMR Berghofer Medical Research Institute), Amelia Roman Aguilera(QIMR Berghofer Medical Research Institute), Ailin Lepletier(Griffith University), Tobias Bald(QIMR Berghofer Medical Research Institute), Courtney Beers(Rapt Therapeutics (United States)), Jason Madore(QIMR Berghofer Medical Research Institute), Vanessa B. Soros(Rapt Therapeutics (United States)), Simon C. Robson(Beth Israel Deaconess Medical Center), Ashmitha Sundarrajan(QIMR Berghofer Medical Research Institute), Maike Effern(University of Bonn), Nishamol Geetha(QIMR Berghofer Medical Research Institute), Tracy dela Cruz(Rapt Therapeutics (United States)), Bradley N. Spatola(Rapt Therapeutics (United States)), Kyohei Nakamura(QIMR Berghofer Medical Research Institute), Clifford Wong(Rapt Therapeutics (United States)), Achim K. Moesta(Rapt Therapeutics (United States)), Célia Jacoberger-Foissac(Institute for Research in Immunology and Cancer), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), Mika Casey(QIMR Berghofer Medical Research Institute), Ana C. Anderson(Brigham and Women's Hospital), John Corbin(Rapt Therapeutics (United States)), Megan J. Welch(ARC Centre of Excellence for Coral Reef Studies), Haiyan Zhang(University of Macau), Christos Xiao(QIMR Berghofer Medical Research Institute), Nicola Waddell(QIMR Berghofer Medical Research Institute), Alana G. Lerner(Rapt Therapeutics (United States)), Michele W.L. Teng(The University of Queensland)
Cited by 269
Related Papers
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
Negative feedback control of neuronal activity by microglia
|Nature|2020|997
The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance
|Purinergic Signalling|2006|928